Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Solid Tumor Target Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for LIV-1/ZIP6/SLC39A6 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LIV-1 ECD-Fc Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View LIV-1 Products |
| Gene Delivery | LIV-1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based functional assays. |
View LIV-1 Products |
| Benchmark Ab | Anti-LIV-1 Recombinant Antibody Sequence derived from Ladiratuzumab. Recombinant positive control for binding and internalization. |
View LIV-1 Products |
| Validator | LIV-1 siRNA Set For target knockdown verification and specificity validation. |
View LIV-1 Products |
| Related Target A | TROP2 Co-expressed in triple-negative breast cancer (TNBC); key comparator/combination target in ADC pipelines. |
View TROP2 Products |
| Related Target B | HER2 Synergistic target in breast oncology; critical for evaluating cross-reactivity and combination strategies. |
View HER2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of Multi-pass Transmembrane Target | Lentivirus-driven full-length expression preserves native 8-transmembrane conformation on host cell membranes. |
| Internalization Rate Quantification (ADC Validation) | Sequence-verified clinical benchmark antibodies (Ladiratuzumab biosimilar) for direct comparison in flow cytometry. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live LIV-1/ZIP6/SLC39A6 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for LIV-1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to Antibody-Drug Conjugates (ADCs). As first-generation therapies reach the clinic, the next wave of R&D is targeting drug-resistant subpopulations and exploring novel linker-payload technologies. LIV-1 (SLC39A6), a zinc transporter highly expressed in breast, prostate, and ovarian cancers, represents a premier target for selective intracellular drug delivery due to its rapid internalization kinetics.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC (Antibody-Drug Conjugate) | Pfizer (Seagen) | Triple-Negative Breast Cancer (TNBC), Solid Tumors | Internalization Assay (Need high-purity ECD-Fc and Lentivirus for cell lines) |
| Bispecific Antibody | Biotech Innovators | Metastatic Breast Cancer | Heterodimer Validation (Need Cross-reactive Abs and stable co-expression) |
| Small Molecule Inhibitor | Academic / Discovery Stage | Zinc-transport-associated malignancies | Selectivity Assay (Need Mutant vs WT Proteins, ZIP family panel) |